Citation Impact
Citing Papers
Cutting Edge: TIGIT Has T Cell-Intrinsic Inhibitory Functions
2011
Gut Microbiota Regulates K/BxN Autoimmune Arthritis through Follicular Helper T but Not Th17 Cells
2016
Head‐to‐head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: Findings of a phase IIIb, multinational, prospective, randomized study
2012
Infections requiring hospitalization in the abatacept clinical development program: an epidemiological assessment
2010
Tumor necrosis factor alpha drugs in rheumatoid arthritis: systematic review and metaanalysis of efficacy and safety
2008
Satb1 regulates the effector program of encephalitogenic tissue Th17 cells in chronic inflammation
2019 StandoutNobel
Transcriptional and epigenetic basis of Treg cell development and function: its genetic anomalies or variations in autoimmune diseases
2020 StandoutNobel
A clinical study assessing the tolerability and biological effects of infliximab, a TNF-α inhibitor, in patients with advanced cancer
2008
Ontology and Function of Fibroblast-Like and Macrophage-Like Synoviocytes: How Do They Talk to Each Other and Can They Be Targeted for Rheumatoid Arthritis Therapy?
2018
The Rheumatoid Arthritis Drug Development Model: a case study in Bayesian clinical trial simulation
2009
The safety of anti-tumour necrosis factor treatments in rheumatoid arthritis: meta and exposure-adjusted pooled analyses of serious adverse events
2008
Current evidence for the management of rheumatoid arthritis with biological disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of RA
2010
NF-κB signaling in inflammation
2017 Standout
Golimumab, a new human anti–tumor necrosis factor α antibody, administered intravenously in patients with active rheumatoid arthritis: Forty‐eight–week efficacy and safety results of a phase III randomized, double‐blind, placebo‐controlled study
2010
Targeting Interleukin-6 Signaling in Clinic
2019
Rheumatoid arthritis
2018 Standout
Rheumatoid arthritis
2016 Standout
Synovial Tissue Inflammation Mediated by Autoimmune T Cells
2019 StandoutNobel
The microbiota in adaptive immune homeostasis and disease
2016 StandoutNature
Review article: minimizing tuberculosis during anti‐tumour necrosis factor‐alpha treatment of inflammatory bowel disease
2007
Golimumab in patients with active rheumatoid arthritis despite methotrexate therapy: 52-week results of the GO-FORWARD study
2010
The IL-17 Family of Cytokines in Health and Disease
2019
Risk Factors for Opportunistic Infections in Patients With Inflammatory Bowel Disease
2008
SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trials
2013 Standout
Induction of Inflammatory Arthropathy Resembling Rheumatoid Arthritis in Mice Transgenic for HTLV-I
1991 Science
Anti-IL-17 therapy in treatment of rheumatoid arthritis: a systematic literature review and meta-analysis of randomized controlled trials
2016
Incidence and Prevalence of Rheumatoid Arthritis, Based on the 1987 American College of Rheumatology Criteria: A Systematic Review
2006
Ulcerative Colitis Practice Guidelines in Adults (Update): American College of Gastroenterology, Practice Parameters Committee
2004 Standout
Crohn's disease
2012 Standout
Recent insights in the epidemiology of autoimmune diseases: Improved prevalence estimates and understanding of clustering of diseases
2009
Biologics and heart failure in rheumatoid arthritis: are we any wiser?
2008
Therapies for Active Rheumatoid Arthritis after Methotrexate Failure
2013
Aberrant intestinal microbiota due to IL-1 receptor antagonist deficiency promotes IL-17- and TLR4-dependent arthritis
2017
Prospective comparative study of patients with culture proven and high suspicion of adult onset septic arthritis
2003
The Risk of Infections with Biologic Therapies for Rheumatoid Arthritis
2009
Rheumatoid arthritis in the developing world
2003
Cell-autonomous and -non-autonomous roles of CTLA-4 in immune regulation
2011 StandoutNobel
Psoriasis
2021 Standout
Tumor-Associated Macrophages: From Mechanisms to Therapy
2014 Standout
Interaction between microbiota and immunity in health and disease
2020 Standout
Mitochondrial Myopathy Caused by Long-Term Zidovudine Therapy
1990 Standout
Systematic Review and Meta-Analysis of the Efficacy and Safety of Existing TNF Blocking Agents in Treatment of Rheumatoid Arthritis
2012
The IL-23–IL-17 axis in inflammatory arthritis
2015
A wider spectrum of spondyloarthropathies
1990
Molecular mechanisms underpinning T helper 17 cell heterogeneity and functions in rheumatoid arthritis
2017
Use of abatacept in rheumatoid arthritis
2012
TNFα in the regulation of Treg and Th17 cells in rheumatoid arthritis and other autoimmune inflammatory diseases
2016
Graphical Tools for Network Meta-Analysis in STATA
2013 Standout
Avidin as a model for charge driven transport into cartilage and drug delivery for treating early stage post-traumatic osteoarthritis
2013 StandoutNobel
Rheumatoid arthritis therapy reappraisal: strategies, opportunities and challenges
2015
Epidemiology of eight common rheumatic diseases in China: a large-scale cross-sectional survey in Beijing
2011
Th17 Cell Pathway in Human Immunity: Lessons from Genetics and Therapeutic Interventions
2015
Chronic inflammatory diseases: Do immunological patterns drive the choice of biotechnology drugs? A critical review
2014
Safety and Efficacy of the Selective Costimulation Modulator Abatacept in Patients with Rheumatoid Arthritis Receiving Background Methotrexate: A 5-year Extended Phase IIB Study
2009
Malignancies in the rheumatoid arthritis abatacept clinical development programme: an epidemiological assessment
2008
The environment, geo-epidemiology, and autoimmune disease: Rheumatoid arthritis
2010
Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register (BSRBR)
2009
TNFα blockade in human diseases: An overview of efficacy and safety
2007
Animal models of arthritis caused by systemic alteration of the immune system
2005 StandoutNobel
Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2010
2011 Standout
Effects of Iron Supplementation and Depletion on Hypoxic Pulmonary Hypertension
2009 StandoutNobel
Resistance to Direct Antiviral Agents in Patients With Hepatitis C Virus Infection
2009
Lag-3, Tim-3, and TIGIT: Co-inhibitory Receptors with Specialized Functions in Immune Regulation
2016 Standout
HIV as the cause of AIDS
1996 StandoutNobel
Mixing the right hepatitis C inhibitor cocktail
2010
Rheumatoid arthritis
2010 Standout
Zidovudine-associated myopathy
1989
Rheumatoid arthritis: pathological mechanisms and modern pharmacologic therapies
2018
BSR and BHPR rheumatoid arthritis guidelines on safety of anti-TNF therapies
2010
IL-12 and IL-23 cytokines: from discovery to targeted therapies for immune-mediated inflammatory diseases
2015
The Assessment of SpondyloArthritis international Society classification criteria for peripheral spondyloarthritis and for spondyloarthritis in general
2010 Standout
A network meta-analysis of randomized controlled trials of biologics for rheumatoid arthritis: a Cochrane overview
2009
Most tumour necrosis factor inhibitor trials in rheumatology are undeservedly called 'efficacy and safety' trials: a survey of power considerations
2008
Risks of immunosuppressive therapies including biologic agents in patients with rheumatic diseases and co-existing chronic viral infections
2007
Abatacept for Rheumatoid Arthritis: A Cochrane Systematic Review
2010
Efficacy of biological disease-modifying antirheumatic drugs: a systematic literature review informing the 2016 update of the EULAR recommendations for the management of rheumatoid arthritis
2017
Cancer-related inflammation and treatment effectiveness
2014 Standout
Macrophage Cytokines: Involvement in Immunity and Infectious Diseases
2014 Standout
The increase in pulmonary arterial pressure caused by hypoxia depends on iron status
2008 StandoutNobel
Regulatory T Cell-Specific Epigenomic Region Variants Are a Key Determinant of Susceptibility to Common Autoimmune Diseases
2020 StandoutNobel
Cancer-related inflammation
2008 StandoutNature
Human Immunodeficiency Virus Infection and AIDS in a Person with Negative Serology
1997 StandoutNobel
Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease
2013 Standout
Rheumatoid Arthritis
2008
Performance of the 2011 ACR/EULAR preliminary remission criteria compared with DAS28 remission in unselected patients with rheumatoid arthritis
2012
Cancer-related inflammation, the seventh hallmark of cancer: links to genetic instability
2009 Standout
Inflammatory bone loss: pathogenesis and therapeutic intervention
2012 Standout
Nrf2 activation improves experimental rheumatoid arthritis
2023 StandoutNobel
Staphylococcus aureus Infections: Epidemiology, Pathophysiology, Clinical Manifestations, and Management
2015 Standout
HIV Population Dynamics in Vivo: Implications for Genetic Variation, Pathogenesis, and Therapy
1995 StandoutScience
Regulatory T Cells and Human Disease
2020 StandoutNobel
Actinomyces and Related Organisms in Human Infections
2015 Standout
Psoriasis Pathogenesis and Treatment
2019 Standout
Pulmonary Arterial Hypertension
2006
Risk of Hospitalized Bacterial Infections Associated With Biologic Treatment Among US Veterans With Rheumatoid Arthritis
2014
Efficient Replication of Genotype 3a and 4a Hepatitis C Virus Replicons in Human Hepatoma Cells
2012 StandoutNobel
Description of the Efficacy and Safety of Three New Biologics in the Treatment of Rheumatoid Arthritis
2010
Novel TNF antagonists for the treatment of rheumatoid arthritis
2009
Fundamental Mechanisms of Immune Checkpoint Blockade Therapy
2018 StandoutNobel
Secukinumab in Active Rheumatoid Arthritis: A Phase III Randomized, Double‐Blind, Active Comparator– and Placebo‐Controlled Study
2017
Cytokine Storm
2020 Standout
Induction of autoimmune disease by deletion of CTLA-4 in mice in adulthood
2016 StandoutNobel
Pathogenesis of human immunodeficiency virus infection
1993
Response of Hepatitis C Virus to Long-Term Passage in the Presence of Alpha Interferon: Multiple Mutations and a Common Phenotype
2013 StandoutNobel
Increased Replicative Fitness Can Lead to Decreased Drug Sensitivity of Hepatitis C Virus
2014 StandoutNobel
Prosthetic Joint Infection
2014 Standout
ACCF/AHA 2009 Expert Consensus Document on Pulmonary Hypertension
2009 Standout
Enigma of IL-17 and Th17 Cells in Rheumatoid Arthritis and in Autoimmune Animal Models of Arthritis
2016
Risk of Tuberculosis Reactivation in Patients with Rheumatoid Arthritis, Ankylosing Spondylitis, and Psoriatic Arthritis Receiving Non-Anti-TNF-Targeted Biologics
2017
Systematic Review: Comparative Effectiveness and Harms of Disease-Modifying Medications for Rheumatoid Arthritis
2008
Hepatitis C Virus Genotype 5a Subgenomic Replicons for Evaluation of Direct-Acting Antiviral Agents
2014 StandoutNobel
Impaired T cell receptor signaling and development of T cell–mediated autoimmune arthritis
2020 StandoutNobel
Nod2 Deficiency Augments Th17 Responses and Exacerbates Autoimmune Arthritis
2018 StandoutNobel
Works of Alberto Berman being referenced
The safety of infliximab, combined with background treatments, among patients with rheumatoid arthritis and various comorbidities: A large, randomized, placebo‐controlled trial
2006
Rheumatic manifestations associated with human immunodeficiency virus infection
1989
Rheumatic manifestations of human immunodeficiency virus infection
1988
Psoriatic arthritis and acquired immunodeficiency syndrome
1988
Efficacy and safety of abatacept or infliximab vs placebo in ATTEST: a phase III, multi-centre, randomised, double-blind, placebo-controlled study in patients with rheumatoid arthritis and an inadequate response to methotrexate
2007
Factors Associated With Disability in Patients With Rheumatoid Arthritis
2010
Systemic lupus erythematosus-associated pulmonary hypertension: good outcome following sildenafil therapy
2003
HIV associated arthropathy: HIV antigen demonstration in the synovial membrane.
1990
2001 PHASE 2 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF NITAZOXANIDE PLUS PEGINTERFERON AND RIBAVIRIN IN HCV GENOTYPE 1 NAIVE PATIENTS: WEEK 12 SUSTAINED VIROLOGIC RESPONSE RATE
2010
Human immunodeficiency virus-associated rheumatic disorders in the HAART era.
2004
1049 PHASE 2 RANDOMIZED, DOUBLE-BLIND, PLACEBO- CONTROLLED STUDY OF NITAZOXANIDE PLUS PEGINTERFERON AND RIBAVIRIN IN HCV GENOTYPE 1 PATIENTS: INTERIM ANALYSIS SHOWS INCREASE IN EVR
2009
Prevalence of rheumatoid arthritis in Tucumán, Argentina.
2002
The Efficacy and Safety of Subcutaneous Clazakizumab in Patients With Moderate‐to‐Severe Rheumatoid Arthritis and an Inadequate Response to Methotrexate: Results From a Multinational, Phase IIb, Randomized, Double‐Blind, Placebo/Active‐Controlled, Dose‐Ranging Study
2015
A Phase II Randomized Study of Subcutaneous Ixekizumab, an Anti–Interleukin‐17 Monoclonal Antibody, in Rheumatoid Arthritis Patients Who Were Naive to Biologic Agents or Had an Inadequate Response to Tumor Necrosis Factor Inhibitors
2014